

### IN THE CLAIMS

Please amend claims 1, 2, 8, 10, 13, 14, 21, 24 and 25 to read as follows:

- C1
1. (Amended) A composition for the treatment of a disease involving active angiogenesis which comprises a tubulin binding agent together with an inhibitor of the formation of nitric oxide in a mammalian system.
2. (Amended) A composition for the damage of the formation of new vasculature by angiogenesis comprising a combination of a tubulin binding agent and an inhibitor of nitric oxide synthase in an amount sufficient to augment the effect of the tubulin binding agent.
- C2
8. (Amended) A composition according to claim 4 wherein the derivative of citrulline is selected from L-thiocitrulline, L-homothiocitrulline or an S-alkylthiocitrulline.
- C3
10. (Amended) A composition according to claim 1 wherein the composition is in the form of a kit, one part of the kit comprising the tubulin binding agent and the second part of the kit the nitric oxide inhibitor.
- C4
13. (Amended) A method of treatment for a mammal having a disease involving active angiogenesis, said method comprising administration of a tubulin binding agent and an inhibitor of formation of nitric oxide in an amount sufficient to augment the effect of the tubulin binding agent.
14. (Amended) A method according to claim 13 wherein the tubulin binding agent and nitric oxide inhibitor are administered substantially simultaneously but separately to the mammal under treatment.
- C5
21. (Amended) A composition according to claim 4 wherein the derivative of citrulline is S-methyl-L-thiocitrulline.
24. (Amended) A composition according to claim 1 or 2 wherein the tubulin binding agent is selected from N-acetylcolchicol and its prodrugs.
- C6
25. (Amended) A composition according to claim 1 or 2 wherein the tubulin binding agent is N-acetylcolchicol-O-phosphate.

Please cancel claims 6, 16, 18, 22 and 23.

### REMARKS

The amended claim is set out in the Appendix showing the amendments made.